Overview
A healthcare group built around one chain.
Pranda Health is a healthcare group headquartered in Orlando, Florida, operating across active pharmaceutical ingredients, finished dosage manufacturing, global supply chain and clinical services in the United States.
Overview
What the group is.
The group owns manufacturing facilities and operates alongside affiliated group facilities, with API and finished-dosage capability in Hyderabad and Visakhapatnam, India, and an established healthcare presence in the United States.
Management has described a platform with more than twenty years in business, supported by approximately thirty years of healthcare experience, and supply experience across multiple international markets.
That structure is the point rather than a detail. A great deal of pharmaceutical trade is conducted by parties who introduce a buyer to a manufacturer and then step back. When a batch is delayed, a dossier stalls or a shelf empties, there is frequently nobody whose own operations are on the line. We are built the other way: the entity holding the commercial relationship is connected to the entities that make the product.
Where we operate
Four locations, one chain.
Orlando, Florida — United States
Group headquarters. Commercial leadership, programme governance, international supply planning and market development.
Hyderabad, India
Formulation development and finished dosage manufacturing, with corporate and research activity. Modified-release pellet technology is the core technical specialism.
Visakhapatnam, India
Active pharmaceutical ingredient and intermediate manufacture, supporting internal consumption for the group’s finished-dose portfolio as well as external supply.
Clinical operations — United States
The group also operates healthcare facilities in the United States. That side of the business is not a marketing adjacency: it is the reason we treat continuity of supply as a clinical obligation rather than a logistics metric.
How we operate
Four principles, applied consistently.
Health need comes first
Portfolios are built from shortage risk, predictable demand and national health priorities — not from whatever is easiest to ship or most profitable to land.
Regulatory pathways are respected
Approval in one country never substitutes for local authorisation. Nothing is supplied until the applicable national pathway is complete, and we say so even when it slows us down.
Measured, not asserted
Performance is tracked on a scorecard the customer can see: fill rate, stockout days, lead time, on-time-in-full delivery, expiry, complaint closure and recall readiness.
Each stage earns the next
Capability deepens only after demand, regulatory performance and cost competitiveness have been demonstrated with real data — not projected in a business case.
The group at a glance
The numbers, stated plainly.
Figures reflect management-supplied information as at August 2026. Company registration details, site scopes and licence particulars are provided in a credential appendix on request.
A note on claims
We would rather under-state than be corrected.
Pharmaceutical credentials are easy to blur and consequential to overstate. WHO-GMP certification is not WHO product prequalification. Construction to EU-GMP standards is not EU-GMP certification. Exporting to a market is not the same as holding that market’s approval.
We hold ourselves to those distinctions in writing. Certificates, licence numbers, site scopes, validity dates and inspection histories belong in a credential appendix a counterparty can verify — not in marketing copy. If a claim is not currently documented, it does not appear on this website.
Next step
Ask us for the credential appendix.
Site scopes, licences, validity dates and inspection history — shared directly with counterparties who need to verify them.